Cure Alveolar Soft Part Sarcoma International (iCureASPS)

Hey everyone, it has been a while since my last update. I have been on Pembro and Axi for over one year now and the response has been mixed. The 3- and 6- month update scans showed one new brain met each (~5mm) and both have been treated with SRS. Also the nodule in the lung increased by about 1mm ...

Hey, another update. I had new scans after 4 months and the results were kind of mixed. So the brain is mostly stable except the left occipital lesion seems to have grown just a bit (<1mm). This is the same one that showed growth together with the large necrotic one. Also the MRI showed a lesion be...

Concluding remarks Tumour relapse is a complex and poorly defined phenomenon that limits our ability to completely cure cancer. Several studies have highlighted the presence of slow-cycling or slow-proliferating cancer cells and senescent cancer cell populations in tumours, neither of which are targ...

Immune gene signatures as prognostic criteria for cancer patients Abstract Recently, the possibility of using immune gene signatures (IGSs) has been considered as a novel prognostic tool for numerous cancer types. State-of-the-art methods of genomic, transcriptomic, and protein analysis have allowe...

Main Text Introduction Successful generation of a T cell-mediated immunity to eliminate antigen includes but it is not limited to the following steps: (1) tumor-antigen uptake and processing by antigen-presenting cells (APCs), (2) migration of APCs to lymphoid organs, (3) tumor-antigen presentation ...

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on amplifying immune activation mechanisms that are employed by humans to el...

5. Conclusions Bone is a special immune site with a unique immunosuppressive microenvironment. Bone metastasis impairs immunotherapy efficacy, especially when used alone. Even it is not true in all the trials, bone targeted therapies appear to have a synergistic effect when used in combination with ...

Discussion and Future Perspectives While the majority of breast and prostate cancer patients with bone metastasis are treated with bone targeted therapy, currently only about 50–60% of patients with NSCLC are treated with bone-specific drugs [7,14]. This is due to the fact that, until a few years ag...

Hypoxia as a driver of resistance to immunotherapy Abstract Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive malignant clones displaying resistance to radiotherapy, conventional chemotherapy or targeted therapy. The recent introduction of immunotherapy, based ...

Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma Background: Tumor angiogenesis, or new blood vessel formation, is regulated by a balance between pro-angiogenic factors such as vascular endothelial growth factor (VEGF) ...

Continued from 2018☺️ Table 3. Summary of responders to immunotherapies in this study. Percentage is the number of responders out of the total number treated with that particular histologic subtype Sarcoma type Best response # responders total % Alveolar soft part Partial response 2-4 50.0% Alveolar...

The role of CEMIP in tumors: An update based on cellular and molecular insights Abstract CEMIP was initially identified as an inner-ear specific protein in which three-point mutations cause folding changes in protein structure associated with non-syndromic hearing loss. CEMIP was also involved in o...

“A "low mutational burden but lots of neoantigens" situation refers to a cancer where the overall number of genetic mutations in the tumor is relatively low, but the few mutations that are present still produce a significant amount of unique "neoantigens" that the immune system c...

Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas Sarcomas are mesenchymal tumors, encompassing more than 175 subtypes, each one with their own genetic complexities. As a result, immunotherapy approaches have not been universally successful across the wide range of diverse subtypes. The actua...

Ivan
Excellent news!